|
10/06/2025
|
13:28
|
TR-1
|
RNS
|
|
06/06/2025
|
15:12
|
Notice of AGM and Annual Report & Accounts
|
RNS
|
|
04/06/2025
|
14:34
|
Director/PDMR Shareholding
|
RNS
|
|
04/06/2025
|
07:00
|
Preliminary results for the year ended 31 Dec 2024
|
RNS
|
|
14/05/2025
|
16:02
|
PDS: Q1 Results and Clinical and Corporate Update
|
RNS
|
|
09/05/2025
|
10:30
|
TR-1
|
RNS
|
|
27/03/2025
|
16:46
|
PDS: Q4 Results and Clinical Programs Update
|
RNS
|
|
07/03/2025
|
16:26
|
PDS: VERSATILE-003 Phase 3 Clinical Trial
|
RNS
|
|
27/02/2025
|
16:30
|
PDS: up to $22mn Registered Direct Offering
|
RNS
|
|
05/02/2025
|
15:24
|
PDS Biotech reaffirms guidance for clinical trial
|
RNS
|
|
03/02/2025
|
07:00
|
ProAxsis: Status Update and Proposed Fundraise
|
RNS
|
|
06/01/2025
|
16:42
|
TR-1
|
RNS
|
|
31/12/2024
|
07:05
|
Grant of Share Options
|
RNS
|
|
31/12/2024
|
07:00
|
Q-Bot Fundraising
|
RNS
|
|
12/12/2024
|
16:49
|
TR-1
|
RNS
|
|
09/12/2024
|
07:00
|
Wanda Health Fundraising
|
RNS
|
|
05/12/2024
|
07:00
|
Close of Fundraising and Result of Retail Offer
|
RNS
|
|
03/12/2024
|
13:24
|
Result of Subscription
|
RNS
|
|
03/12/2024
|
07:05
|
WRAP Retail Offer
|
RNS
|
|
03/12/2024
|
07:00
|
Proposed Subscription and Retail Offer; Update
|
RNS
|
|
14/11/2024
|
15:59
|
Replacement RNS: PDS: Update, 3rd Quarter Results
|
RNS
|
|
14/11/2024
|
15:23
|
PDS: Clinical Programs Update, 3rd Quarter Results
|
RNS
|
|
08/10/2024
|
07:00
|
Director/PDMR Shareholding
|
RNS
|
|
02/10/2024
|
16:38
|
PDS: 36-Month Overall Survival Rate announcement
|
RNS
|
|
03/10/2024
|
07:00
|
Director/PDMR Shareholding
|
RNS
|
|
30/09/2024
|
07:00
|
Interim Results
|
RNS
|
|
26/09/2024
|
07:00
|
Name change and AIM Rule 26 website
|
RNS
|